Tam S, Yao CMK, Amit M, et al. - In this retrospective cohort study, researchers determined the risks for mortality in patients with cutaneous squamous cell carcinoma (cSCC) and immunosuppression vs nonimmunosuppression and compared the difference in mortality risk based on the cause of immunocompromise. From January 1, 1995, to September 30, 2015, patients who had no treatment, wide local excision, or biopsy of the lesions were eligible for inclusion. According to their immune status (immunosuppression vs no immunosuppression), participants were divided into two groups. Seven hundred ninety-six patients (680 men [85.4%]; median age, 69 [range, 27-98] years) with cSCC were included. According to findings, immunosuppression was independently linked to a worse outcome in cSCC, with a 2.32 times raised the risk of disease-specific death after adjusting for age, history of skin cancer, recurrent or persistent disease status, disease stage, and treatment.